Seasonal influenza virus is associated with considerable morbidity and mortality each year in the United States. Most people recover from influenza illness without requiring medical attention; however, among those who are immunocompromised, influenza can cause severe illness, complications, and death. Patients who are immunocompromised experience greater morbidity and mortality from vaccine-preventable illnesses, including influenza, due to an insufficient immune response. Because of these risks, influenza vaccination is a critical strategy to prevent infection in this patient population.

FDA has granted an Emergency Use Authorization (EUA) for the combined test of the BD MAX Molecular Diagnostic System by Becton, Dickinson, and Company for SARS-CoV-2, influenza A+B, and respiratory syncytial virus. respiratory tract (RSV).